Document:

<Page>

                                                                   EXHIBIT 10.24

                                January 27, 2006

Matthew Sherman
[ADDRESS]

Dear Matthew:

     The purpose of this letter agreement is to set forth our mutual
understanding and agreement with respect to your separation from employment with
Synta Pharmaceuticals Corp.. (the "Company"). In consideration of the mutual
covenants set forth herein, the receipt and sufficiency of which you
acknowledge, we have agreed as follows:

     1.   SEPARATION FROM EMPLOYMENT. Your separation from employment shall be
          effective as of the close of business on Friday, January 27, 2006
          (your "separation date"), and you shall have relinquished as of that
          date any and all positions that you have held with the Company. You
          shall not be considered an employee of the Company for any purpose
          after that date.

     2.   TERMINAL PAY. You agree that you have received all compensation to
          which you are entitled in connection with your employment through your
          separation date. You agree to make no claims for further compensation
          from the Company of any type, including bonus payments, commission
          payments, and vacation pay. You acknowledge that, except to the extent
          provided herein, the Company is under no obligation to provide you
          with the benefits described below.

     3.   SALARY CONTINUATION. You will be paid a lump sum of $285,000 less all
          applicable federal, state or local tax withholding, F.I.C.A., and any
          other applicable payroll deductions, which is equal to 12 months of
          base pay at your current annual rate, subject to the following
          conditions: (a) the Company's receipt of this Agreement signed by you,
          d (b) the expiration of the seven-day revocation period referenced in
          Paragraph 19 of this Agreement without you providing notice of
          revocation of this Agreement.

     4.   INSURANCE CONTINUATION: Your medical and life insurance and short term
          and long term disability coverage terminates on your last day of
          employment. At your option, you may continue to be covered under the
          Company's group medical insurance plan up to eighteen (18) months
          after your separation date, subject to the terms and conditions
          provided for in the Consolidated Omnibus Budget Reconciliation Act of
          1985, as amended "COBRA." See enclosed letter describing your COBRA
          options. During the period from January 28, 2006 through January 27,
          2007 your cost for medical coverage will be the same as it would be
          had you continued as an active employee subject to the following
          conditions: (a) the Company's receipt of this Agreement signed by you,
          and (b) the expiration of the seven-day revocation period referenced
          in Paragraph 16 of this Agreement without you providing notice of
          revocation of this Agreement. You will be responsible for the full

<Page>

          COBRA premium for medical coverage for the balance of the 18 month
          COBRA period if you choose the coverage.

     5.   STOCK OPTIONS. You may exercise any stock options that are vested on
          the last day of active employment pursuant to the terms of the
          applicable option agreement and the Synta Pharmaceutical 2001 Stock
          Plan. Copies of the Plan and option exercise forms are attached.

     6.   TRANSFER OF RESPONSIBILITIES. You shall cooperate fully with the
          Company and its personnel to provide an orderly transfer of your
          duties and responsibilities. This cooperation includes but is not
          limited to timely compliance with all reasonable requests for
          information.

     7.   EMPLOYMENT AT THE COMPANY. You agree that you shall not seek or accept
          employment with the Company either now or in the future and the
          Company has no obligation to employ you in any capacity.

     8.   CONFIDENTIALITY. You agree, to the extent permitted by law, to keep
          confidential and not to disclose the existence or terms of this letter
          agreement or sums paid under this letter agreement to anyone (in the
          company or outside) or to any organization, except you may disclose
          such information to your spouse, attorney, and financial advisor,
          provided you have received in advance their promises to maintain this
          information in strict confidence; provided, however, that nothing in
          this Agreement will prevent you from cooperating with or participating
          in any proceeding before the EEOC, the MCAD or any other federal,
          state or local agency or entity. You also agree that you will not,
          without the Company's prior written consent, reveal or disclose to any
          person or entity outside of the Company or use for your own benefit or
          for the benefit of any other person or entity, any confidential
          information concerning the business or affairs of the Company, or
          concerning the Company's customers, clients, or employees
          ("Confidential Information").

     9.   RETURN OF PROPERTY. You acknowledge that you will return to the
          Company all property of the Company that is in your possession or
          under your control, including, without limitation, computer
          accessories, pager, corporate credit card, telephone card, fax
          machine, Company keys, and any and all files, documents and other
          information with respect to the Company's management, business
          operations or customers, including all files, documents, or other
          information containing Confidential Information.

     10.  MODIFICATION TO EXHIBIT A OF FEBRUARY 12, 2004 EMPLOYMENT OFFER. You
          and the Company agree to delete the last sentence of Paragraph
          1(a)(ii) of Exhibit A and replace it with the following: A BUSINESS
          WILL BE DEEMED COMPETITIVE WITH THE COMPANY ONLY IF IT ENGAGES IN THE
          RESEARCH, DEVELOPMENT, MANUFACTURE, DISTRIBUTION AND/OR SALE OF ANY OF
          THE PRODUCTS RESEARCHED, DEVELOPED, MANUFACTURED, DISTRIBUTED AND/OR
          SOLD BY THE COMPANY WITHIN THE FIELD OF INTEREST (AS DEFINED BELOW)
          DURING THE PERIOD OF YOUR EMPLOYMENT WITH THE COMPANY. FOR CLARITY,
          PRODUCTS RESEARCHED, DEVELOPED, MANUFACTURED, DISTRIBUTED AND/OR SOLD
          BY THE COMPANY WITHIN THE FIELD OF INTEREST DURING THE PERIOD OF YOUR
          EMPLOYMENT WITH THE COMPANY INCLUDE THE COMPANY'S

                                       2
<Page>

          HSP90 INHIBITORS, HSP70 INDUCERS, CRAC INHIBITORS, MT INHIBITORS,
          INCLUDING THOSE THAT DISRUPT VASCULATURE, C-REL INHIBITORS AND
          IL-12/23 INHIBITORS.

     11.  JOB FINDING ASSISTANCE. The Company agrees to pay an amount up to
          $10,000.00 to an organization to provide you with job finding and
          other outplacement assistance.

     12.  ADDITIONAL PAYMENT RELATED TO CONSULTING SERVICES. Subject to
          satisfying the provisions of a Consulting Agreement dated January 30,
          2006, the Company agrees to pay you the following additional amounts:
          (a) $20,000.00 on April 1, 2006, (b) $10,000.00 on May 1, 2006 and (c)
          $10,000.00 on June 1, 2006. It is agreed that any of the amounts
          described above will not be payable if you become employed on a full
          time basis prior to the date on which the payment is earned.

     13.  NON-DISPARAGEMENT.

          (a)  You further agree, to the extent permitted by law, that you will
               not, at any time after the date hereof, make any remarks or
               comments, orally or in writing, to actual or potential customers,
               investors, collaborators, regulators or others, which or who have
               or could reasonably be anticipated to have, business dealings
               with the Company, which remarks or comments reasonably could be
               construed to be derogatory or disparaging to the Company or any
               of its shareholders, officers, directors, employees, attorneys or
               agents, or which reasonably could be anticipated to be damaging
               or injurious to the Company's reputation or good will or to the
               reputation or good will of any person associated with the
               Company.

          (b)  The Company further agrees, to the extent permitted by law, that
               it will not, at any time after the date hereof, make any remarks
               or comments, orally or in writing, to actual or potential
               employers, associates or others, which or who have, or could
               reasonably be anticipated to have, business dealings with you,
               which remarks or comments reasonably could be construed to be
               derogatory or disparaging to you, or which reasonably could be
               anticipated to be damaging or injurious to the your reputation or
               good will or to the reputation or good will of any person
               associated with you in a business relationship.

     14.  NON-DISCLOSURE AND RELATED UNDERSTANDINGS. You acknowledge the
          validity and continuing applicability of the agreements and covenants
          contained in the Confidentiality and Inventions Agreement concerning
          the non-use and return of confidential information and non-competition
          with the Company, except as modified by paragraph 10 above.

     15.  COOPERATION IN LITIGATION. At the Company's request, you agree to
          assist, consult with, and cooperate with the Company in any litigation
          or administrative procedure or inquiry that involves the Company,
          subject to reimbursement for your reasonable out of pocket expenses,
          such as travel, meals, or lodging. In the event that you become a
          party to any litigation or administrative proceeding or inquiry by
          virtue of your status as an officer and/or employee of the Company,
          the Company agrees that the defense and indemnification rights set
          forth in the Company's By-Laws, and pursuant to any

                                       3
<Page>

          applicable insurance policies, remain in full force and effect and are
          not altered in any respect by this letter agreement.

     16.  BREACH OF AGREEMENT. You understand and agree that any breach of your
          obligations under this letter agreement will immediately render the
          Company's obligations and agreements hereunder null and void, and, to
          the extent permitted by law, you shall repay to the Company all sums
          you have been paid or sums paid on your behalf pursuant to paragraph 3
          & 4. The Company also reserves the right to take appropriate legal
          action against you if warranted under the circumstances.

     17.  (A). GENERAL RELEASE OF COMPANY. You, for yourself and your heirs,
          legal representatives, beneficiaries, assigns and successors in
          interest, hereby knowingly and voluntarily release, remise and forever
          discharge the Company and its successors, assigns, former, current or
          future officers, directors, employees, agents, attorneys and
          representatives, whether in their individual or official capacities
          ("the Company Released Parties), from any and all actions or causes of
          action, suits, debts, claims, complaints, contracts, controversies,
          agreements, promises, damages, claims for attorneys' fees, costs,
          interest, punitive damages or reinstatement, judgments and demands
          whatsoever, in law or equity, you now have, may have or ever had,
          whether known or unknown, suspected or unsuspected, from the beginning
          of the world to this date, including, without limitation, any claims
          under the Age Discrimination in Employment Act, 29 U.S.C.ss.621 et
          seq., Title VII of the Civil Rights Act of 1964, 42 U.S.C.ss.2000e et
          seq.; the Employee Retirement Income Security Act of 1974, as amended,
          29 U.S.C.ss.1000 et seq., Massachusetts General Laws, Chapter 151B;
          the Americans with Disabilities Act, 42 U.S.C.ss. 12101 et seq.;
          claims for breach of contract or based on tort; and any other
          statutory, regulatory or common law causes of action. YOU HEREBY
          ACKNOWLEDGE AND UNDERSTAND THAT THIS IS A GENERAL RELEASE AND THAT YOU
          ARE RELEASING ALL RIGHTS TO SUE THE COMPANY RELEASED PARTIES FOR ANY
          ACTION OR OMISSION UP TO AND INCLUDING THE DATE OF THE EXECUTION OF
          THIS AGREEMENT.

          (B). GENERAL RELEASE OF EMPLOYEE. The Company and its successors,
          assigns, former or current shareholders, officers, directors,
          employees, agents, attorneys, and representatives hereby knowingly and
          voluntarily release, remise, and forever discharge you and your heirs,
          legal representatives, beneficiaries, assigns, and successors in
          interest ("Employee Released Parties") from any and all actions or
          causes of action, suits, debts, claims, complaints, contracts,
          controversies, agreements, promises, damages, claims for attorneys
          fees, costs, interest, punitive damages or reinstatement, judgments,
          and demands whatsoever, in law or equity, the Company now has, may
          have, or ever had, whether known or unknown, suspected or unsuspected,
          from the beginning of the world to this date (the "Released Claims").
          THE COMPANY HEREBY ACKNOWLEDGES AND UNDERSTANDS THAT THIS IS A GENERAL
          RELEASE AND THAT THE COMPANY IS RELEASING ALL RIGHTS TO SUE YOU FOR
          ANY. ACTION OR OMISSION UP TO AND INCLUDING THE DATE OF THE EXECUTION
          OF THIS AGREEMENT

     18.  (A). COVENANT NOT TO SUE COMPANY RELEASED PARTIES. To the extent
          permitted by law, you specifically agree not to commence any legal
          action against any of the Company Released Parties arising out of or
          in connection with the Released Claims. To the extent permitted by
          law, you expressly agree that if you continence such an action in
          violation

                                      4
<Page>

          of this Agreement, you shall indemnify the Company Released Parties
          for the full and complete costs of defending such an action and
          enforcing this Agreement, including reasonable attorneys' fees
          (whether incurred in a third party action or in an action to enforce
          this Agreement), court costs, and other related expenses. You further
          agree that, to the extent permitted by law, if you commence such an
          action despite the provisions of this Agreement, you shall be
          obligated to return to the Company the full amount of all sums paid to
          you, or on your behalf, pursuant to Paragraph 3 & 4.

          B. COVENANT NOT TO SUE EMPLOYEE RELEASED PARTIES. To the extent
          permitted by law, the Company specifically agrees not to commence any
          legal action against any of the Employee Released Parties arising out
          of or in connection with the Released Claims. To the extent permitted
          by law, the Company expressly agrees that if the Company or its
          successors,. assigns, former or current shareholders, officers,
          directors, employees, agents, attorneys, or representatives commence
          such an action in violation of this Agreement, the Company shall
          indemnify the Employee Released Parties for the full and complete
          costs of defending such an action and enforcing this Agreement,
          including reasonable attorneys fees (whether incurred in a third party
          action or in an action to enforce this Agreement), court costs, and
          other related expenses. The Company agrees that if the Company or its
          successors, assigns, former or current shareholders, officers,
          directors, employees, agents, attorneys, or representatives commence
          such an action despite the provisions of this Agreement, the Company
          shall relinquish all rights under. this Agreement (including without
          limitation the last sentence of paragraph 15a) to obtain a return of
          any sums paid to you, or on your behalf, pursuant to Paragraphs 3 and
          4.

     19.  ACKNOWLEDGMENT. You acknowledge and agree that you understand the
          meaning of this Agreement and that you freely and voluntarily enter
          into it and the General Release contained herein. You agree that no
          fact, evidence, event, or transaction occurring before the execution
          of this Agreement, which is currently unknown to you, but which may
          hereafter become known to you, shall affect in any manner the final
          and unconditional nature of the. agreements and releases set forth
          herein. You acknowledge that you have been advised to consult with an
          attorney prior to executing this Agreement and that you have
          twenty-one (21) days to consider this Agreement. For a period of seven
          (7) days after executing this Agreement, you may revoke this Agreement
          by providing written notice of such revocation to Stephen M. Gansler.
          This Agreement shall not become effective or enforceable until this
          (7) seven-day period has expired. The revocation of this Agreement by
          you shall render this Agreement null and void.

     20.  MISCELLANEOUS. This letter agreement shall be construed in accordance
          with the laws of the Commonwealth of Massachusetts without regard to
          choice or conflict of law principles. A waiver of any breach of or
          failure to comply fully with any provision of this letter agreement by
          either party shall not operate or be construed as a waiver of any
          subsequent breach thereof or failure so to comply. If any portion or
          provision of this letter agreement shall to any extent be deemed
          invalid or unenforceable, the remainder of this letter agreement shall
          not be affected thereby and each portion and provision of this letter
          agreement shall be valid and enforceable to the fullest extent
          permitted. To avoid any possible misunderstanding, the Company intends
          this letter agreement to be a comprehensive statement of the terms of
          your separation. This letter agreement

                                       5
<Page>

          supersedes any prior understanding or statement made to you by the
          Company regarding your positions with the Company or your arrangements
          with the Company for the period after your separation. For the same
          reason, any modifications of the terms set forth in this letter
          agreement must be in writing and signed by you and by me on behalf of
          the Company.

Please indicate your agreement to the terms of this letter agreement by signing
and dating the last page of the enclosed copy of this letter agreement, and
return it to Stephen M. Gansler not later than the close of business on
February 14, 2006. In the event that you do not understand any terms or
conditions specified in this letter of agreement, the Company urges you to seek
legal counsel prior to signing and returning this letter.

                                          Sincerely,

                                          /s/ STEPHEN M. GANSLER
                                          --------------------------------------
                                          Stephen M. Gansler
                                          Vice President, Human Resources

AGREED TO AND EXECUTED UNDER SEAL THIS 31 day of January, 2006.

                                          /s/ MATTHEW SHERMAN
                                          --------------------------------------
                                          Matthew Sherman

Signed before me on January 31, 2006 by Matthew Sherman, Personally known to me.

                                          Wendy Rieder

                                       6<Page>

                                                                   EXHIBIT 10.25

Standard Synta Form
Consultant from Industry/Academia(Master)
Approved March 2005

CONSULTANT:                             | MATTHEW SHERMAN, MD
SYNTA CONTACT:                          | ERIC JACOBSON
EFFECTIVE DATE:                         | JANUARY 30, 2006

--------------------------------------------------------------------------------

                                      SYNTA
                                 PHARMACEUTICALS

                              CONSULTING AGREEMENT

     THIS CONSULTING AGREEMENT (together with any Consulting Services Exhibits,
the "Agreement") is made as of the date set forth above (the "Effective Date")
by and between Synta Pharmaceuticals Corp., a Delaware corporation with a
principal place of business at 45 Hartwell Avenue, Lexington, MA 02421 (Tel:
781-274-8200; Fax: 781-274-8228) ("Synta") and the consultant named on the
signature page ("Consultant").

1.   BACKGROUND. This Agreement contains general terms and conditions under
     which Synta may, from time to time, engage Consultant to provide consulting
     services to Synta ("Consulting Services"). Synta and Consultant have agreed
     that Consultant will provide the Consulting Services specified in the
     attached exhibit (the "Consulting Services Exhibit") and in any future
     Consulting Services Exhibits that the parties may mutually agree to and
     execute. Once executed, a Consulting Services Exhibit becomes part of this
     Agreement, although the terms in that exhibit will govern only the
     Consulting Services described in that exhibit. A Consulting Services
     Exhibit may not change any term in this Agreement. Each Consulting Services
     Exhibit will describe the Consulting Services, the time for completion of
     those services, any Proprietary Materials (defined below) to be provided by
     Synta in connection those services, and information about the compensation
     for the Consulting Services.

2.   DEFINITIONS. The following terms have the meanings set forth below:

     2.1  "CONFIDENTIAL INFORMATION" means any non-public scientific, technical,
          business or financial information furnished by or on behalf of Synta
          to Consultant in connection with any Consulting Services or developed
          by Consultant in the course of performing the Consulting Services.
          Confidential Information may include, without limitation, trade
          secrets, know-how, inventions, technical data or specifications,
          testing methods, business or financial information, information
          relating to research and development activities, product and marketing
          plans, and customer and supplier information. Confidential Information
          will also include the existence and content of this Agreement, any
          Consulting Services Exhibits, and any of the terms and conditions
          contained therein. Confidential Information does

<Page>

          not include information that (a) was in the public domain prior to the
          time of its disclosure under this Agreement; (b) entered the public
          domain after the time of its disclosure under this Agreement through
          means other than an unauthorized disclosure resulting from an act or
          omission by Consultant; (c) was independently developed or discovered
          by Consultant without use or reference to Confidential Information; or
          (d) is or was disclosed to Consultant at any time, whether prior to or
          after the time of its disclosure under this Agreement, by a third
          party having no fiduciary relationship with Synta and having no
          obligation of confidentiality to Synta with respect to that
          information.

     2.2  "DEVELOPMENTS" means any and all inventions, developments, data,
          discoveries, improvements, ideas, concepts, computer programs,
          algorithms, protocols, systems and related documentation, and any
          other works of invention or authorship (whether or not patentable,
          copyrightable, or entitled to or eligible for other forms of legal
          protection) that Consultant has conceived, devised, written, invented,
          discovered, developed, or reduced to practice or tangible medium
          (whether alone, jointly with others, or under his or her direction)
          (a) during the course of rendering the Consulting Services or (b)
          through the use of Synta's equipment, facilities, Confidential
          Information or Proprietary Materials, or at Synta's expense.

     2.3  "PROPRIETARY MATERIALS" means all tangible materials furnished by
          Synta, all materials developed by Consultant as a result of rendering
          the Consulting Services and all materials, the cost of which are
          reimbursed to Consultant by Synta hereunder. Materials include, in the
          case of biological materials, all progeny and unmodified derivatives
          of those materials, and in the case of chemical materials, all
          analogs, formulations, mixtures and compositions of those materials.

3.   CONSULTING SERVICES. Consultant agrees to perform the Consulting Services
     as set forth in the applicable Consulting Services Exhibit. Any changes to
     the Consulting Services (and any related compensation adjustments) under
     any particular Consulting Services Exhibit must be agreed to in writing by
     Consultant and Synta prior to commencement of those changes. Consultant
     understands and agrees that it is not the intent of Synta that this
     Agreement or any actions of Synta be construed as imposing any duty or
     obligation, express or implied, on Consultant to use, purchase, prescribe,
     or recommend any Synta product.

4.   CONSULTING RELATIONSHIP. Consultant agrees, as a condition of this
     Agreement, to the following terms:

     4.1  ABSENCE OF RESTRICTIONS. Consultant is under no contractual or other
          obligation or restriction which is inconsistent with Consultant's
          execution of this Agreement or the performance of the Consulting
          Services. During the Term (defined below), Consultant will not enter
          into any Agreement, either written or oral, in conflict with
          Consultant's obligations under this Agreement. Consultant will arrange
          to provide the Consulting Services in such manner and at such times
          that the

                                       2
<Page>

          Consulting Services will not conflict with Consultant's
          responsibilities under any other Agreement, arrangement or
          understanding or pursuant to any employment or other relationship
          Consultant has at any time with any third party.

     4.2  CONSULTANT PERSONNEL. In the event that others are, or may hereafter
          become, associated with Consultant or are used by Consultant in
          connection with the Consulting Services ("Consultant Personnel"),
          Consultant agrees to procure from them agreements containing
          obligations substantially identical in form and content to those in
          this Agreement, and Consultant agrees to cooperate with Synta in
          procuring execution by them of assignments and other papers as may be
          required by the terms of this Agreement.

     4.3  COMPLIANCE WITH POLICIES AND REGULATIONS. In performing the Consulting
          Services, Consultant will, and will cause Consultant Personnel to,
          comply with all business conduct, regulatory, and health and safety
          guidelines or regulations established by Synta or any governmental
          authority with respect to Synta's business. If Consultant is a faculty
          member at or employee of a university or hospital ("Institution") or
          of another company, Consultant represents and warrants that pursuant
          to Institution's or company's policies concerning professional
          consulting and additional workload, Consultant is permitted to enter
          into this Agreement. If Consultant is required by Consultant's
          Institution to disclose to it any proposed agreements with industry,
          Consultant has made that disclosure.

     4.4  ABSENCE OF DEBARMENT. Consultant represents that neither Consultant
          nor any Consultant Personnel has been debarred, and to the best of
          Consultant's knowledge, is not under consideration to be debarred, by
          the U.S. Food and Drug Administration from working in or providing
          consulting services to any pharmaceutical or biotechnology company
          under the Generic Drug Enforcement Act of 1992.

5.   COMPENSATION; PAYMENT. As full consideration for Consulting Services
     rendered under a Consulting Services Exhibit, Synta agrees to pay
     Consultant the compensation set forth in the applicable Consulting Services
     Exhibit. Payment of all undisputed amounts will be made within thirty (30)
     days from Synta's receipt of Consultant's invoice. Invoices will contain
     such detail as Synta may reasonably require and will be payable in U.S.
     Dollars.

6.   CONFIDENTIALITY OBLIGATIONS. During the Term and for a period of five (5)
     years thereafter, Consultant agrees to:

     a. maintain all Confidential Information in strict confidence and not
     disclose Confidential Information to any third parties, except to
     Consultant Personnel who have a need to know such Confidential Information
     in the course of performing their duties under the applicable Consulting
     Services Exhibit, and who are bound to protect the confidentiality of the
     Confidential Information consistent with the terms of this Agreement;

                                       3
<Page>

     b. use all Confidential Information solely for the purpose of providing the
     Consulting Services as requested by Synta; and

     c. reproduce the Confidential Information only to the extent necessary to
     provide the Consulting Services, with all reproductions being considered
     Confidential Information.

If required by law, Consultant may disclose Confidential Information to a
governmental authority, provided that reasonable advance notice is given to
Synta and Consultant reasonably cooperates with Synta to obtain confidentiality
protection of that information.

7.   DEVELOPMENTS.

     7.1  OWNERSHIP. All Developments will be the exclusive property of Synta.
          All work products resulting from the Consulting Services that are
          "Works Made for Hire" as defined in the U.S. Copyright Act and other
          copyrightable works will be deemed, upon creation, to be assigned to
          Synta. Synta may use or pursue them without restriction or additional
          compensation. Consultant will promptly and fully disclose to Synta all
          Developments. Consultant will keep and maintain complete written
          records of all Developments and of all work or investigations done or
          carried out by Consultant. Consultant may keep one (1) copy of these
          records in Consultant's files solely for reference purposes.
          Consultant assigns and agrees to assign to Synta all of Consultant's
          right, title and interest in and to any Developments. During and after
          the Term, Consultant will cooperate fully, and will cause Consultant
          Personnel to cooperate frilly, in obtaining patent and other
          proprietary protection for the Developments, all in the name of Synta
          and at Synta's cost and expense, and, without limitation, will execute
          and deliver all requested applications, assignments and other
          documents, and take such other measures as Synta will reasonably
          request, in order to perfect and enforce Synta's rights in the
          Developments. Consultant appoints Synta its attorney to execute and
          deliver any such documents on Consultant's or Consultant's Personnel's
          behalf in the event Consultant or Consultant Personnel fails to do so.

     7.2  PROPRIETARY MATERIALS. For Consulting Services which involve
          laboratory work or experiments, Consultant agrees not to use or
          evaluate Proprietary Materials for any purpose other than as directed
          by Synta, nor transfer the Proprietary Materials to any third party
          without the prior consent of Synta. Consultant will use the
          Proprietary Materials in compliance with all applicable laws and
          regulations.

     7.3  THIRD PARTY INTELLECTUAL PROPERTY. The performance of the Consulting
          Services does not and will not breach any agreement which obligates
          Consultant to keep in confidence any confidential or proprietary
          information of any third party or to refrain from competing, directly
          or indirectly, with the business of any third party. Consultant will
          not disclose to Synta any such confidential or proprietary
          information. Unless covered by an appropriate agreement between any
          third party and Synta, Consultant will not engage in any activities or
          use any third party facilities or intellectual property in performing
          the Consulting Services which

                                       4
<Page>

          could result in claims of ownership to any Developments being made by
          a third party.

     7.4  AGREEMENT WITH INSTITUTION. This Agreement is made subject to the
          understanding that Consultant, if affiliated with an Institution, may
          be required to fulfill certain obligations, including teaching,
          directing laboratory operations, conducting research, and publishing
          work. It is further understood that Consultant may have signed an
          agreement concerning inventions with Institution, under which
          Consultant may be obligated to assign to Institution certain
          inventions which arise out of or otherwise relate to Consultant's work
          at or for Institution or from Consultant's use of certain of its
          facilities or intellectual property. In performing the Consulting
          Services, Consultant agrees not to utilize Institution facilities or
          intellectual property if the result of such use is that any
          Developments will not be assignable solely to Synta.

8.   PUBLICATIONS AND PRESENTATIONS. If the performance of the Consulting
     Services gives rise to results that are publishable in scientific or other
     journals, or presentable at professional conferences or other meetings,
     such publications and presentations by the Consultant will be permissible
     only with the prior written approval of Synta. A copy of each proposed
     publication or any proposed presentation material will be provided to Synta
     at least thirty (30) days in advance of submission to third parties to
     enable Synta to determine if patentable Developments or any Confidential
     Information of Synta would be disclosed. Consultant will cooperate with
     Synta in this respect and will delete from the manuscript or other
     disclosure any Confidential Information if requested by Synta, and will
     assist Synta in filing for patent protection for any patentable
     Developments described in those documents, prior to publication or other
     disclosure. Synta will also receive final drafts of any proposed
     publication or presentation material and Synta will be named in the
     publication or presentation as Synta and the Consultant agree is
     appropriate.

9.   TERM AND TERMINATION.

     9.1  TERM. This Agreement will commence on the Effective Date and will
          expire on the later of (a) two (2) years from the Effective Date or
          (b) the completion of all Consulting Services under the last
          Consulting Services Exhibit executed by the parties prior to the
          second anniversary of the Effective Date ("Term"). This Agreement may
          be extended by mutual agreement of the parties or earlier terminated
          in accordance with Section 9.2 or 9.3 below.

     9.2  TERMINATION BY SYNTA. Synta may immediately terminate this Agreement
          at any time upon written notice to Consultant in the event of a breach
          or threatened breach of this Agreement by Consultant which cannot be
          cured (such as breach or threatened breach of any confidentiality
          obligations hereunder). Further, Synta may terminate this Agreement or
          any Consulting Services Exhibit at any time upon thirty (30) days'
          prior written notice to Consultant.

     9.3  TERMINATION BY CONSULTANT. Consultant may terminate this Agreement
          upon two (2) weeks' prior written notice to Synta, or as otherwise
          agreed by the parties.

                                       5
<Page>

     9.4  EFFECT OF EXPIRATION/TERMINATION. Upon expiration or termination of
          this Agreement, neither Consultant nor Synta will have any further
          obligations under this Agreement, or in the case of expiration or
          termination of a Consulting Services Exhibit, under that exhibit,
          except that (a) Consultant will terminate all Consulting Services in
          progress in an orderly manner as soon as practical and in accordance
          with a schedule agreed to by Synta, unless Synta specifies in the
          notice of termination that Consulting Services in progress should be
          completed, (b) Consultant will deliver to Synta any Proprietary
          Materials in its possession or control and all Developments made
          through expiration or termination, (c) Synta will pay Consultant any
          monies due and owing Consultant, up to the time of expiration or
          termination, for Consulting Services actually performed and all
          authorized expenses actually incurred (as specified in the applicable
          Consulting Services Exhibit), (d) Consultant will immediately return
          to Synta all Confidential Information and copies thereof provided to
          Consultant under this Agreement or under any Consulting Services
          Exhibit which has expired or been terminated, except for one (1) copy
          which Consultant may retain solely to monitor Consultant's surviving
          obligations of confidentiality, and (e) the terms of Sections 2, 6, 7,
          8, 9.4, 10.2, 10.3, 10.5, and 10.7 through 10. 11, will survive.

10.  MISCELLANEOUS.

     10.1 INDEPENDENT CONTRACTOR; TAXES.

          a.   INDEPENDENT CONTRACTOR. All Consulting Services will be rendered
               by Consultant as an independent contractor and this Agreement
               does not create an employer-employee relationship between Synta
               and Consultant. Consultant will have no rights to receive any
               employee benefits, such as health and accident insurance, sick
               leave or vacation which are accorded to regular Synta employees.
               Consultant will not in any way represent himself to be an
               employee, partner, joint venturer, agent or officer with or of
               Synta. Neither Synta nor Consultant will have any obligation,
               responsibility or authority to act on behalf of or in the name of
               the other, or to bind the other in any manner whatsoever. Any
               representation to the contrary to Consultant or the Synta or the
               employees or agents of either, will be sufficient grounds for
               immediate termination of this Agreement.

          b.   TAXES. Consultant will pay all required taxes on Consultant's
               income from Synta under this Agreement. Consultant will provide
               Synta with Consultant's taxpayer identification number or social
               security number, as applicable. Failure to furnish such
               information may result in withholding of payments to Consultant
               in accordance with Internal Revenue Service regulations.

     10.2 PUBLICITY. Consultant consents to the use by Synta of Consultant's
          name and likeness in written materials and oral presentations to
          current or prospective customers, partners, investors or others,
          provided that such materials or presentations accurately describe the
          nature of Consultant's relationship with or

                                       6
<Page>

          contribution to Synta. Synta consents to the use by Consultant of
          Synta's name on lists of its clients provided that the nature of the
          Consulting Services is accurately described and that Synta has had the
          opportunity to review and approve the publicity.

     10.3 NOTICES. All notices must be written and sent to the address or
          facsimile number identified in this Agreement or a subsequent notice.
          All notices must be given (a) by personal delivery, with receipt
          acknowledged, (b) by facsimile followed by hard copy delivered by the
          methods under (c) or (d), (c) by prepaid certified or registered mail,
          return receipt requested, or (d) by prepaid recognized next business
          day delivery service. Notices will be effective upon receipt or as
          stated in the notice. Notices to Synta must be marked "ATTENTION: VICE
          PRESIDENT, LEGAL AFFAIRS".

     10.4 ASSIGNMENT. This Agreement is a personal services agreement, and the
          rights and obligations hereunder, may not be assigned or transferred
          by either party without the prior written consent of the other party.
          Synta may, however, assign this Agreement, in whole or in part, to a
          subsidiary or affiliate, or in connection with a merger,
          consolidation, or a sale or transfer of all or substantially all of
          the assets to which this Agreement relates.

     10.5 ENTIRE AGREEMENT. This Agreement (together with the Consulting
          Services Exhibits) constitutes the entire agreement of the parties
          with regard to its subject matter, and supersedes all previous written
          or oral representations, agreements and understandings between Synta
          and Consultant.

     10.6 NO MODIFICATION. This Agreement may be changed only by a writing
          signed by authorized representatives of both parties.

     10.7 SEVERABILITY; REFORMATION. Each provision in this Agreement is
          independent and severable from the others, and no provision will be
          rendered unenforceable as a result of any other provision(s) being
          held to be invalid or unenforceable in whole or in part. If any
          provision of this Agreement is invalid, unenforceable or too broad,
          that provision will be appropriately limited and reformed to the
          maximum extent permitted by applicable law.

     10.8 GOVERNING LAW. This Agreement will be construed and interpreted and
          its performance governed by the laws of the Commonwealth of
          Massachusetts, without giving effect to the doctrine of conflict of
          laws.

     10.9 WAIVER. No waiver of any term, provision or condition of this
          Agreement (whether by conduct or otherwise) in any one or more
          instances will be deemed to be or construed as a further or continuing
          waiver of any such term, provision or condition of this Agreement.

    10.10 COUNTERPARTS. This Agreement may be executed in any number of
          counterparts, each of which will be deemed to be an original and all
          of which together will constitute one and the same instrument.

                                       7
<Page>

    10.11 HEADINGS. This Agreement contains headings only for convenience and
          the headings do not constitute or form a part of this Agreement, and
          should not be used in the construction of this Agreement.

SYNTA PHARMACEUTICALS CORP.                   MATTHEW SHERMAN, MD

By:  /s/ JEREMY CHADWICK                      /s/ MATTHEW SHERMAN
    --------------------                      --------------------

Print Name: Jeremy G. Chadwick                Print Name: Matthew Sherman
            -------------------                           ---------------

Title:  Vice President, Program Management &
        Clinical Operations duly authorized

                                       8
<Page>

                           CONSULTING SERVICES EXHIBIT

     This CONSULTING SERVICES EXHIBIT (the "Consulting Services Exhibit") is
made and entered into as of the date set forth above ("Exhibit Effective Date")
by and between Synta Pharmaceuticals Corp. ("Synta") and the consultant
identified above (the "Consultant") and upon execution will be incorporated into
the Agreement between Synta and Consultant dated as of the Agreement Effective
Date set forth above ("Agreement"),

     1.   Consultant will provide medical Consulting Services to Synta. Such
          services may include, but will not be limited to:

          1.)  Completing the draft Clinical Development Plan for the melanoma
               indication for STA-4783

          2.)  Assist with review and interpretation of the STA-4783 sarcoma
               data

          3.)  Create high level "Clinical Development Plan" for Hsp90 program

               i.   Create plan for initial indication(s) with rationale for
                    indications chosen

               ii.  Design high level clinical trial synopsis/synopses for
                    "First in person" studies

          4.)  Assist with phase 3 development strategy for STA-5326 in Crohn's
               disease

          5.)  Participate as core team member for the Hsp90 program (meetings
               every other Wednesday 10 am to noon)

          6.)  Assist with transition of CMO responsibilities

          Consultant will be available to render Consulting Services two (2)
          days per week on-site (Tuesdays and Wednesdays), or on a schedule to
          be determined by mutual arrangement between Consultant and the Synta
          Contact named above, to whom Consultant will report. In addition,
          Consultant will be available for a reasonable number of telephone
          and/or written consultations.

          Synta will provide the following Proprietary Materials to Consultant
          in connection with the Consulting Services: Clinical Development
          Plans, Protocols, Study Data, and other documents needed for
          Consultant to provide Consulting Services.

2.       COMPENSATION AND EXPENSES:

          As full compensation for the Consulting Services, Synta will pay
          Consultant $312 per hour during the Consulting Services Tenn. The
          amount of such payment

                                       9
<Page>

          represents the fair market value for the Consulting Services that
          Consultant has agreed to render.

          The compensation under this Consulting Services Exhibit it will not
          exceed $94,864, without the prior written approval of Synta (17 weeks
          x 16 hours per week x $312 per hour = $84,864 + $10,000 estimated
          travel expenses).

          Synta will reimburse Consultant for all reasonable travel and other
          expenses incurred by Consultant in rendering the Consulting Services,
          provided that such expenses are agreed upon in writing in advance, and
          are confirmed by appropriate written expense statements and other
          supporting documentation.

          On a monthly basis, Consultant will invoice Synta for Consulting
          Services rendered and expenses incurred during the preceding month.
          All invoices will be sent to: Accounts Payable, Synta Pharmaceuticals
          Corp., 45 Hartwell Ave., Lexington, MA 02421 and will contain the
          detail required by Synta.

     3.   CONSULTING SERVICES TERM. The term of this Consulting Services Exhibit
          will be for an initial period of four (4) months, beginning on the
          Exhibit Effective Date, and may be extended by mutual agreement of
          Consultant and Synta or earlier terminated in accordance with Section
          9 of the Agreement.

     4.   AGREEMENT. All terms and conditions of the Agreement will apply to the
          Consulting Services rendered under this Consulting Services Exhibit.

AGREED TO AND ACCEPTED BY:

Synta Pharmaceuticals Corp.                        Matthew Sherman, MD

By: /s/ JEREMY CHADWICK                            /s/ MATTHEW SHERMAN
    --------------------                           -----------------------

Print Name: JEREMY G. CHADWICK                     Print Name: MATTHEW SHERMAN
            ------------------                                 ---------------

Title: VICE PRESIDENT, PROGRAM MANAGEMENT
       & CLINICAL OPERATIONS
       duly authorized
                                     --------------------------------
                                          SYNTA PHARMACEUTICALS

                                            PURCHASE ORDER NO.

                                                  060266

                                      Please include this number on
                                      all correspondence, invoices,
                                         reports, payments, etc.,
                                         regarding this agreement
                                     ---------------------------------

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]